# Vanzacaftor PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vanzacaftor

> The FDA approved vanzacaftor, sponsored by VERTEX PHARMACEUTICALS INC / MA (VRTX), on December 20, 2024 for people with CF 6 years of age and older.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is vanzacaftor FDA approved?

Yes. The FDA approved vanzacaftor, sponsored by VERTEX PHARMACEUTICALS INC / MA (VRTX), on December 20, 2024 for people with CF 6 years of age and older. SEC Form 8-K: "On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK." [Calendar and source filings](https://sec-api.dev/pdufa/vanzacaftor)

Source: SEC Form 8-K, accession 0000875320-24-000231, https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm (retrieved 2026-11-12). Last confirmed 2025-11-04. Cite: https://sec-api.dev/pdufa/vanzacaftor#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | vanzacaftor |
| Codes |  |
| Sponsor | VERTEX PHARMACEUTICALS INC / MA (VRTX) https://sec-api.dev/companies/vrtx/catalysts |
| Indications | people with cf 6 years of age and older, cf 6 years of age and older, cystic fibrosis in people 6 years and older |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 20, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: people with CF 6 years of age and older.
- First seen 2024-12-20, last confirmed 2025-11-04.
- SEC Form 8-K (accession 0000875320-24-000231): "On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK." https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm
- SEC Form 10-Q (accession 0000875320-25-000232): "In December 2024, the U.S. Food and Drug Administration (the "FDA") approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our once-daily next-in-class triple combination for the treatment of people with CF 6 years of age and older, and our fifth CF medicine." https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/vrtx-20250930.htm
- SEC Form 10-Q (accession 0000875320-25-000216): "In December 2024, the U.S. Food and Drug Administration (the "FDA") approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our once-daily next-in-class triple combination for the treatment of people with CF 6 years of age and older, and our fifth CF medicine." https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm
- SEC Form 10-Q (accession 0000875320-25-000192): "In December 2024, the U.S. Food and Drug Administration (the "FDA") approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our once-daily next-in-class triple combination for the treatment of people with CF 6 years of age and older, and our fifth CF medicine." https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm
- SEC Form 10-K (accession 0000875320-25-000053): "In December 2024, the U.S. Food and Drug Administration (the "FDA") approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our fifth medicine for people with CF." https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm
- SEC Form 10-K (accession 0000875320-25-000053): "•In 2017, we enhanced our CF portfolio through our acquisition of certain CF assets, including deutivacaftor, from Concert Pharmaceuticals Inc. In December 2024, the FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for people with CF 6 years of age and older." https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm
- SEC Form 10-K (accession 0000875320-25-000053): "In December 2024, the U.S. Food and Drug Administration (the "FDA") approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our once-daily next-in-class triple combination for the treatment of people with CF 6 years of age and older, and our fifth CF medicine." https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vanzacaftor.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vanzacaftor PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vanzacaftor

```bibtex
@misc{secapidev_pdufa_vanzacaftor_20261116,
  title        = {Vanzacaftor PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vanzacaftor}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vanzacaftor_20261116","title":"Vanzacaftor PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vanzacaftor","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
